Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period

Abstract Introduction Induction therapy has been recently adopted for intestinal transplant. Patients and methods We compared during first 30 days post-transplantation 29 recipients, allocated in two groups, treated with Daclizumab (Zenapax® ) or Alemtuzumab (Campath-1H® ). Results During first mont...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Digestive and liver disease 2007-03, Vol.39 (3), p.253-256
Hauptverfasser:	Lauro, A, Amaduzzi, A, Dazzi, A, Ercolani, G, Zanfi, C, Golfieri, L, Grazi, G.L, Vivarelli, M, Cescon, M, Varotti, G, Del Gaudio, M, Ravaioli, M, Siniscalchi, A, Faenza, S, D’Errico, A, Di Simone, M, Pironi, L, Pinna, A.D
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Alemtuzumab Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antibodies, Neoplasm - therapeutic use Daclizumab Female Gastroenterology and Hepatology Graft Rejection - prevention & control Graft Survival Humans Immunoglobulin G - therapeutic use Immunosuppression Immunosuppressive Agents - therapeutic use Induction therapy Intestines - transplantation Male Postoperative Period Transplantation, Homologous Viscera - transplantation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!